Patricio M Polanco1,2, Ali A Mokdad1, Hong Zhu3, Michael A Choti1, Sergio Huerta1,2. 1. Department of Surgery, University of Texas Southwestern Medical Center, Dallas. 2. Department of Veterans Affairs North Texas Health Care System, Dallas. 3. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas.
Abstract
Importance: Adjuvant chemotherapy (AC) in patients with rectal cancer with pathologic complete response following neoadjuvant chemoradiotherapy (nCRT) and resection is recommended by treatment guidelines. However, its role in this setting is equivocal because data supporting benefits are lacking. Objective: To compare the overall survival (OS) between AC and postoperative observation (OB) in patients with rectal cancer with pathologic complete response following nCRT and resection. Design, Setting, and Participants: We identified a cohort of patients with rectal cancer and a complete pathological response (ypT0N0) after nCRT in the National Cancer Database between 2006 and 2012. Patients who received AC were compared with OB patients by propensity score matching. Overall survival was compared using the stratified log-rank test and stratified Cox regression model. The outcomes after AC vs OB were also evaluated in patient subgroups. The data analysis was completed in June 2017. Exposures: Adjuvant chemotherapy and OB. Main Outcomes and Measures: Overall survival. Results: We identified 2764 patients (mean [SD] age, 60.0 [12.3] years; 40% female) with clinical stage II or III resected adenocarcinoma of the rectum who had received nCRT and were complete responders (ypT0N0M0). Of this cohort, 741 patients in the AC group were matched by propensity score to 741 patients who underwent OB. The AC cohort had better OS compared with the OB cohort (hazard ratio, 0.50; 95% CI, 0.32-0.79). The 1-, 3-, and 5-year OS rates were 99.7%, 97.1%, and 94.7% for the AC group and 99.2%, 93.6%, and 88.4% for the OB group (P = .005). In subgroup analysis, patients with clinical stage T3/T4 and node-positive disease benefited most from AC (hazard ratio, 0.47; 95% CI, 0.25-0.91). Conclusions and Relevance: Adjuvant chemotherapy was associated with improved OS in patients with pathologic complete response after nCRT for resected locally advanced rectal cancer. This study supports the use of AC in this setting where there is currently paucity of data.
Importance: Adjuvant chemotherapy (AC) in patients with rectal cancer with pathologic complete response following neoadjuvant chemoradiotherapy (nCRT) and resection is recommended by treatment guidelines. However, its role in this setting is equivocal because data supporting benefits are lacking. Objective: To compare the overall survival (OS) between AC and postoperative observation (OB) in patients with rectal cancer with pathologic complete response following nCRT and resection. Design, Setting, and Participants: We identified a cohort of patients with rectal cancer and a complete pathological response (ypT0N0) after nCRT in the National Cancer Database between 2006 and 2012. Patients who received AC were compared with OBpatients by propensity score matching. Overall survival was compared using the stratified log-rank test and stratified Cox regression model. The outcomes after AC vs OB were also evaluated in patient subgroups. The data analysis was completed in June 2017. Exposures: Adjuvant chemotherapy and OB. Main Outcomes and Measures: Overall survival. Results: We identified 2764 patients (mean [SD] age, 60.0 [12.3] years; 40% female) with clinical stage II or III resected adenocarcinoma of the rectum who had received nCRT and were complete responders (ypT0N0M0). Of this cohort, 741 patients in the AC group were matched by propensity score to 741 patients who underwent OB. The AC cohort had better OS compared with the OB cohort (hazard ratio, 0.50; 95% CI, 0.32-0.79). The 1-, 3-, and 5-year OS rates were 99.7%, 97.1%, and 94.7% for the AC group and 99.2%, 93.6%, and 88.4% for the OB group (P = .005). In subgroup analysis, patients with clinical stage T3/T4 and node-positive disease benefited most from AC (hazard ratio, 0.47; 95% CI, 0.25-0.91). Conclusions and Relevance: Adjuvant chemotherapy was associated with improved OS in patients with pathologic complete response after nCRT for resected locally advanced rectal cancer. This study supports the use of AC in this setting where there is currently paucity of data.
Authors: Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin Journal: J Clin Oncol Date: 2011-07-11 Impact factor: 44.544
Authors: A J Breugom; W van Gijn; E W Muller; Å Berglund; C B M van den Broek; T Fokstuen; H Gelderblom; E Kapiteijn; J W H Leer; C A M Marijnen; H Martijn; E Meershoek-Klein Kranenbarg; I D Nagtegaal; L Påhlman; C J A Punt; H Putter; A G H Roodvoets; H J T Rutten; W H Steup; B Glimelius; C J H van de Velde Journal: Ann Oncol Date: 2014-12-05 Impact factor: 32.976
Authors: R Glynne-Jones; N Counsell; P Quirke; N Mortensen; A Maraveyas; H M Meadows; J Ledermann; D Sebag-Montefiore Journal: Ann Oncol Date: 2014-04-08 Impact factor: 32.976
Authors: Clémence Leyrat; Shaun R Seaman; Ian R White; Ian Douglas; Liam Smeeth; Joseph Kim; Matthieu Resche-Rigon; James R Carpenter; Elizabeth J Williamson Journal: Stat Methods Med Res Date: 2017-06-02 Impact factor: 3.021
Authors: Karin M Hardiman; Alexis G Antunez; Arielle Kanters; Ari D Schuman; Scott E Regenbogen Journal: J Surg Oncol Date: 2019-04-16 Impact factor: 3.454